Brokerages expect that Endologix, Inc. (NASDAQ:ELGX) will report $35.26 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Endologix’s earnings. The lowest sales estimate is $35.00 million and the highest is $35.58 million. Endologix reported sales of $34.76 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 1.4%. The firm is expected to announce its next quarterly earnings report on Thursday, November 7th.

On average, analysts expect that Endologix will report full year sales of $142.70 million for the current year, with estimates ranging from $142.10 million to $143.85 million. For the next fiscal year, analysts expect that the firm will post sales of $150.91 million, with estimates ranging from $150.00 million to $152.07 million. Zacks’ sales averages are an average based on a survey of analysts that follow Endologix.

Endologix (NASDAQ:ELGX) last announced its quarterly earnings results on Thursday, August 8th. The medical instruments supplier reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.43. The firm had revenue of $36.24 million during the quarter, compared to analysts’ expectations of $36.09 million. Endologix had a negative net margin of 60.32% and a negative return on equity of 154.23%.

A number of research analysts have commented on ELGX shares. Zacks Investment Research upgraded shares of Endologix from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research note on Wednesday. Royal Bank of Canada set a $7.00 price target on shares of Endologix and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, ValuEngine raised shares of Endologix from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Zacks Investment Management bought a new stake in Endologix in the 2nd quarter valued at $108,000. Jane Street Group LLC bought a new stake in Endologix in the 2nd quarter valued at $91,000. D. E. Shaw & Co. Inc. lifted its position in Endologix by 6.9% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 177,931 shares of the medical instruments supplier’s stock valued at $1,288,000 after acquiring an additional 11,497 shares in the last quarter. First Light Asset Management LLC acquired a new stake in Endologix in the 2nd quarter valued at $17,828,000. Finally, Morgan Stanley increased its stake in Endologix by 1,395.2% in the 2nd quarter. Morgan Stanley now owns 722,419 shares of the medical instruments supplier’s stock valued at $5,230,000 after buying an additional 674,103 shares during the last quarter. 48.44% of the stock is owned by institutional investors.

ELGX traded down $0.30 during midday trading on Friday, reaching $6.11. 244,410 shares of the company’s stock were exchanged, compared to its average volume of 240,310. The company has a market cap of $113.78 million, a price-to-earnings ratio of -0.85 and a beta of 0.37. The company has a quick ratio of 0.90, a current ratio of 1.58 and a debt-to-equity ratio of 11.12. Endologix has a one year low of $5.20 and a one year high of $26.50. The company’s 50-day moving average is $6.81.

Endologix Company Profile

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system.

Read More: Why are percentage gainers important?

Get a free copy of the Zacks research report on Endologix (ELGX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Endologix (NASDAQ:ELGX)

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with's FREE daily email newsletter.